Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CEFACLOR vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Acute otitis media,Acute exacerbations of chronic bronchitis,Pharyngitis/tonsillitis,Uncomplicated skin and skin structure infections,Urinary tract infections,Lower respiratory tract infections including pneumonia
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
250-500 mg orally every 8 hours
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic (minor); primarily renally excreted unchanged.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
25-50% bound to plasma proteins, primarily albumin
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.35-0.5 L/kg; distributes into most body tissues and fluids, including middle ear, sinus, and respiratory secretions
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: 95% well absorbed; food does not significantly affect absorption
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl 10-50 m L/min: 50% of usual dose every 8 hours; Cr Cl <10 m L/min: 50% of usual dose every 12 hours
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No adjustment required for mild to moderate hepatic impairment; safety in severe impairment not established
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
20-40 mg/kg/day orally divided every 8 hours; maximum 1 g/day
Not approved for pediatric patients <18 years; safety and efficacy not established.
No specific adjustment, but monitor renal function; initiate at lower end of dosing range due to age-related renal decline
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
None.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Hypersensitivity reactions, including anaphylaxis,Clostridium difficile-associated diarrhea,Seizures (especially with renal impairment),Prolonged PT in patients on anticoagulants,False-positive urine glucose test
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Known hypersensitivity to cephalosporins or any component,Previous immediate hypersensitivity reaction to penicillins (cross-sensitivity)
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No significant food interactions; cefaclor can be taken with or without food.,Absorption may be slightly delayed with food but total bioavailability is unaffected.,Avoid grapefruit juice? No known interaction.,Alcohol: No specific interaction, but caution as it may increase side effects like gastrointestinal upset.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimester: No known fetal risks; Cefaclor crosses the placenta with fetal serum concentrations approximately 10-20% of maternal levels.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Cefaclor is excreted into human breast milk in low concentrations (M/P ratio approximately 0.05-0.10). Considered compatible with breastfeeding by the American Academy of Pediatrics; use with caution in nursing infants with potential for diarrhea or allergic sensitization.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No dose adjustment required in pregnancy; pharmacokinetic changes (increased volume of distribution, renal clearance) do not necessitate dose modification due to wide therapeutic index.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Cefaclor is a second-generation cephalosporin with activity against both Gram-positive and Gram-negative organisms, but not Pseudomonas or MRSA.,It is stable against some beta-lactamases, but resistance can occur via extended-spectrum beta-lactamases (ESBLs).,Dose adjustment is required in renal impairment (Cr Cl <40 m L/min).,It is available as an oral suspension and capsules; suspension must be refrigerated and shaken well before use.,Cefaclor may cause a serum sickness-like reaction, especially in children, characterized by rash, arthralgia, and fever.,It has a short half-life (0.6-0.9 hours) and is usually dosed every 8 hours.,Avoid use in patients with immediate hypersensitivity to penicillins due to cross-reactivity risk (about 10%).
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take this medication exactly as prescribed, usually every 8 hours, with or without food.,Complete the full course of therapy even if you feel better to prevent bacterial resistance.,Shake the oral suspension well before each dose and refrigerate it; discard any unused portion after 14 days.,Contact your healthcare provider if you develop severe diarrhea, rash, joint pain, or fever.,Inform your doctor if you have a history of allergic reactions to penicillins or cephalosporins.,Do not take this medication if you are allergic to cefaclor or any other cephalosporin antibiotic.,If a dose is missed, take it as soon as remembered unless it is almost time for the next dose; do not double the dose.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"Phenindione, a vitamin K antagonist anticoagulant, potentiates the effect of cefaclor, a second-generation cephalosporin antibiotic. Cefaclor may reduce vitamin K production by suppressing intestinal flora, thereby enhancing the anticoagulant effect of phenindione. This interaction can lead to an increased international normalized ratio (INR) and risk of bleeding, particularly in patients with poor nutritional status or prolonged antibiotic therapy."
"Dicoumarol may increase the anticoagulant activities of Cefaclor."
"Warfarin may increase the anticoagulant activities of Cefaclor."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CEFACLOR vs ABSTRAL, answered by our medical review team.
CEFACLOR is a Cephalosporin Antibiotic that works by Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CEFACLOR and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CEFACLOR is: 250-500 mg orally every 8 hours. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CEFACLOR and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CEFACLOR is classified as Category A/B. First trimester: No increased risk of major congenital malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third t. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.